Six Years, and the Real Story Is the Knee: Decoding Ruti Aga's Ban

In that March half marathon in China, Ruti Aga won the race. Her time is not in any report, no splits, no field depth. What we have is the result — the win — and a sample taken after it. And then, effective 10 September, a six-year ban. This is how I have read these stories for years: lab first, paper second, body third. The news usually arrives in reverse order — medal first, then the sanction that dulls it. The Athletics Integrity Unit (AIU) statement came on Thursday. It carries two elements: a presence violation, and a tampering charge. The six years falls out of those two — two for the first, four for the second. But if you read this story only through the doping lens, you miss the actual lesson. Because the substance named — methylprednisolone — is not an anabolic steroid. Some reports have called it a "prohibited steroid," which is pharmacologically wrong. It is a glucocorticoid, WADA Prohibited List class S9, and under the current List, S9 substances are prohibited in-competition only, by injection, oral or rectal routes. A therapeutic injection given out-of-competition is entirely legal; it becomes a violation only if residues are present in-competition. That distinction is the spine of this case. I have spent three decades on this beat, and I have learned that the biggest reporting error tends to happen at the substance-class level — because change the class and the entire sanction logic changes with it. The knee-injury explanation is mechanistically plausible. Intra-articular or peri-articular methylprednisolone for knee synovitis is standard sports-medicine practice in distance runners. What the AIU statement describes is that Aga cited a knee injury and produced a prescription. The problem was not that the knee was fake. The problem was that the prescription was. According to the statement, the prescription came from a clinic that did not exist. The person who issued it was a family member, not a registered physician. He claimed to have used an "old prescription pad from a former workplace" — and the clinic that pad was attributed to explicitly disowned the claim. Three independent verification failures: no clinic, no doctor, no pad. To me this is not just an athlete's mistake. It is the picture of an athlete operating without a credentialed team physician. In the East African road-running entourage, this is not an exception. In 2026, during the audit of Ross Barkley's Chelsea medical, I watched clubs price risk — every gap in a medical file showed up in transfer fee. For Indian athletes, from Railways leave sanctions to Patiala camp days, I learned the same thing: when medical support is informal, it is not the accident that decides, it is the system. Aga's knee is the entry point to this whole case. A 32-year-old marathoner sits at a delicate point on the age curve — late peak or early decline. Her recent pattern has been selective Major racing plus Asian label races, the standard appearance-fee income model for a 2:18–2:20 runner. Chronic knee trouble, pressure to mask pain — because appearance fees depend on form — and the cheapest, easiest medical option. That is what a glucocorticoid does: damps pain, reduces swelling, lets you run. Handled correctly, with attention to timing and route, it is perfectly legal. And here is the paradox I find most interesting in this case. S9 substances are prohibited in-competition only. On that March morning, had the paperwork been real — real clinic, real doctor, a record of date and dose — a legitimate defence path existed: timing, route, medical necessity. It might have needed a TUE, but at least there would be an argument. The moment she produced a forged prescription, she closed that one path herself. Two years for presence and four for tampering — that arithmetic matches standard Code provisions. Two years means the panel did not accept a no-fault or no-significant-fault reduction that could have cut the presence sanction. And four years is the standard tampering provision. In other words, in the panel's eyes the real offence was the paper, not the pill. But I see something else here, and it concerns appeal. The full timeline is not clear in the statement — which year the March race was, which year the ban ends — and I cannot verify how clearly those dates appear in the official reasoned decision, so I will not speculate. One thing is clear: backdating to 10 September is no relief. It is a procedural adjustment — provisional suspension time counts against the ban, and nothing more is gained. And if we look at the individual, the numbers are brutal. Six years, from age 32 — return age roughly 38. Ethiopia's women's marathon depth is such that even a 2:18–2:20 runner is not automatically selectable. For a 38-year-old with a doping record, the national-team door is practically shut. On paper the ban is six years; in career terms it is life. This will have no effect on Ethiopian women's marathon competitiveness — that I can say with full confidence. Aga's three Major runner-up finishes were commercial-tier results, not conversions into global championship medals. Her removal makes no measurable difference to Ethiopia's medal capacity. What changes is the governance picture. Here I want to put my biggest question. This case will be cited as "six years for a glucocorticoid" — a substance with no proven endurance benefit. One side will call it proof of AIU rigour. The other will call it disproportionate enforcement against East African road runners. Both sides will be partly right. My concern is different. The pattern across the AIU's road-running case list is that the enforcement frontier has shifted from detection to document verification. When an athlete offers an explanation after a first violation, the paper gets checked — and if the paper is fake, the sanction doubles. That trend is sharpest where medical networks are informal and the appearance-fee economy is dense. China's label-race circuit sits exactly at that intersection: large appearance fees, deep East African elite fields, and AIU testing. I will not say Aga should have been spared. A forged prescription is a mistake with no excuse. But I will say that if the only lesson drawn from this case is "tough on fraud," we have read half the story. The question is why that knee was not treated with real paperwork. Why did a 32-year-old elite athlete not have access to a credentialed team physician, a TUE process, and route-specific washout guidance? Until that question is asked, the next case of this kind will arrive from the same entourage, with the same knee, and the same forged pad.